Materials from Immunization Economics’ 2019 iHEA Pre-Congress Session Now Available

As part of the 2019 iHEA biennial world congress in Basel, Switzerland, the Immunization Economics Special Interest Group (SIG) organized a pre-congress session on July 13-14. The program, which focused on the generation and use of information surrounding immunization costing, financing, and value of vaccination, included:

  1. Featured updates on research findings, methodology, and cases;

  2. Concurrent sessions on economic analysis refresher course and implementation/advocacy workshop;

  3. Panel sessions on effective dissemination and future direction.

Access all materials, presentations, photos, and reports from the Immunization Economics iHEA pre-congress session in Basel, July 13-14, 2019 here.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Submissions Open for Special Issue of Vaccines on Estimating Vaccines’ Value and Impact

Estimating the value and public health impact of vaccines is critical to ensure evidence-based policy decision making in nearly all stages, from vaccine development to the introduction/implementation of vaccines in low-resource settings. To foster public health equity, as well as estimate value to local and national economies, concerted efforts are needed to increase the understanding … Continued

New Evidence Shows Investments in Vaccination Produce Even Greater Returns than Previously Thought

This article originally appeared on Gavi’s website.  The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing ten infectious diseases in 94 low- and middle-income countries, including 73 countries that have received support from … Continued

Rotavirus Vaccination is Cost Effective and Saves Lives, New Analysis Finds

In an analysis published in the December issue of The Lancet Global Health, investigators from PATH, the London School of Hygiene & Tropical Medicine, and the US Centers for Disease Control and Prevention, analyzed the potential costs of rotavirus vaccination for 10 successive birth cohorts (from 2018 through 2027) in 73 countries eligible for Gavi support, compared … Continued